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Abstract
Background: Deoxyribonucleic acid (DNA) vaccines are used for experimental immunotherapy of equine melanoma.
The injection of complexed linear DNA encoding interleukin (IL)-12/IL-18 induced partial tumour remission in a clinical
study including 27 grey horses. To date, the detailed mechanism of the anti-tumour effect of this treatment is unknown.
Results: In the present study, the clinical and cellular responses of 24 healthy horses were monitored over 72 h after
simultaneous intradermal and intramuscular application of equine IL-12/IL-18 DNA (complexed with a transfection
reagent) or comparative substances (transfection reagent only, nonsense DNA, nonsense DNA depleted of CG).
Although the strongest effect was observed in horses treated with expressing DNA, horses in all groups treated with
DNA showed systemic responses. In these horses treated with DNA, rectal temperatures were elevated after treatment
and serum amyloid A increased. Total leukocyte and neutrophil counts increased, while lymphocyte numbers decreased.
The secretion of tumour necrosis factor alpha (TNFα) and interferon gamma (IFNγ) from peripheral mononuclear blood
cells ex vivo increased after treatments with DNA, while IL-10 secretion decreased. Horses treated with DNA had significantly
higher myeloid cell numbers and chemokine (C-X-C motif) ligand (CXCL)-10 expression in skin samples at the
intradermal injection sites compared to horses treated with transfection reagent only, suggesting an inflammatory
response to DNA treatment.
In horses treated with expressing DNA, however, local CXCL-10 expression was highest and immunohistochemistry
revealed more intradermal IL-12-positive cells when compared to the other treatment groups.
In contrast to non-grey horses, grey horses showed fewer effects of DNA treatments on blood lymphocyte counts,
TNFα secretion and myeloid cell infiltration in the dermis.
Conclusion: Treatment with complexed linear DNA constructs induced an inflammatory response independent of the
coding sequence and of CG motif content. Expressing IL-12/IL-18 DNA locally induces expression of the downstream
mediator CXCL-10.
The grey horses included appeared to display an attenuated immune response to DNA treatment, although grey horses
bearing melanoma responded to this treatment with moderate tumour remission in a preceding study. Whether the
different immunological reactivity compared to other horses may contributes to the melanoma susceptibility of grey
horses remains to be elucidated.
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Background
Melanoma is one of the most common equine cutaneous
neoplasms [1–3]. Prevalence is up to 80 % in grey horses
older than 15 years, while horses of other colours are
rarely affected by this disease [4, 5]. To date, there is no
satisfactory therapeutic approach available in advanced
cases of grey horse melanoma [1, 4, 6]. One experimen-
tal in vivo approach is immunotherapy with melanoma
antigens and/or immune modulating cytokines encoded
by deoxyribonucleic acid (DNA) vectors taking advan-
tage of systemic effects on metastases [7–9]. Interleukin
(IL)-12 and IL-18 have been employed as they synergis-
tically stimulate cytotoxic T-cells and natural killer cells
[10–12], which are typically involved in anti-tumour
immune responses. The two cytokines improve antigen
presentation [13] and form a link between innate and
adoptive immunity [14, 15]. Furthermore, anti-angiogenic
properties have been described which could contribute to
anti-tumour effects [16, 17].
A moderate decrease in the tumour volume of mela-
nomas was observed by Mählmann et al. [18] during a
study period of 120 days after immunotherapy of 27 grey
horses with mixed linear DNA vectors (minimalistic im-
munologic defined gene expression (MIDGE)-Th1) en-
coding equine IL-12 and IL-18. These DNA vectors were
formulated with the transfection reagent SAINT-18 and
administered simultaneously intramuscularly (i.m.) and
peritumourally intradermally (i.d.).
MIDGE-Th1 vectors are minimalistic linear double-
stranded DNA molecules lacking plasmid backbone
sequences. The vectors are covalently closed with single-
strand hairpin loops at both ends. They contain the
expression cassette only, i.e. a promoter, the coding
sequence of interest and a polyadenylation site [19, 20].
One of the ends is covalently bound to a nuclear local-
isation signal peptide, triggering an improved humoral
and cellular response of a TH1 phenotype [21, 22]. In
vivo transfection is established and can be facilitated by
the formulation of the DNA vectors with cationic lipids,
such as SAINT-18, to form complexes with these mole-
cules [23, 24].
Signs of a systemic immune response, i.e. the develop-
ment of fever 12 h after administration of MIDGE-Th1
formulated with SAINT-18 and the size reduction of me-
tastases which had not been treated locally, were observed
in the study of Mählmann et al. [18]. Local immunological
responses were indicated by signs of acute inflammation
(swelling, reddening, etc.) and depigmentation of the skin
at the site of injection. The exact mechanisms of this anti-
tumour therapy are still unknown.
Effects of DNA vectors are usually explained by their
transgene products [9, 19, 23, 25], by immunologic effects
caused by CG motifs randomly contained in the vector con-
structs which activate toll-like receptor (TLR-) 9 pathways
[26–28], by reactions triggered by interaction with cyto-
solic receptors for dsDNA [29–33], or by combinations of
these effects.
The mechanisms of the immunotherapeutic effects of
MIDGE-Th1 encoding equine IL-12 and IL-18 demon-
strated by Mählmann et al. [18] in grey horses affected
with melanoma need to be elucidated in order to improve
the directed clinical use of anti-tumour treatments. There-
fore, the aim of this study was the characterisation of the
immune response to the treatment by investigation of
various candidate immune parameters on the systemic
and local level in healthy horses. Furthermore, potential
immunologically active components of the therapeutic
were analysed for their contribution to the immune re-
sponse. This was conducted comparatively in four treat-
ment groups, representing effects by transfection reagent




All procedures were carried out according to the ethical
guidelines of the law on animal welfare (Tierschutzgesetz)
approved by the “Niedersächsisches Landesamt für
Verbraucherschutz und Lebensmittelsicherheit” in the
animal experiment No. 33.9-42502-04-11/0399. In-
formed consent was obtained from all animal owners.
Study design
A prospective, randomised, double-blinded study was per-
formed in 24 horses assigned randomly to four groups of
six horses each (A–D) by the criteria of colour, age and
breed (Table 1).
Animals
Clinically healthy horses (6 mares, 15 geldings and 3
stallions) aged between 2 and 21 years (mean 10.6 years)
with a body weight of 425–680 kg (mean 572 kg) were
included in the study. There were six Thoroughbred
(ThB) type horses (two Arabians, two Arabian-mix and
two English ThBs) and 18 Warmblood (WBl) type horses
(nine Hanoverian WBls, one Hessian WBl, one Polish
WBl, two Pura Raza Españolas (PRE), one PRE-mix, one
Standardbred, one Oldenburg WBl, and one Westfalian
WBl; Table 1). One horse of treatment group A had a
history of insect bite hypersensitivity and one horse of
each of the treatment groups A, B and C had a history
of chronic obstructive bronchitis/bronchiolitis, but all
horses were asymptomatic throughout the study period.
No systemic and potentially immunomodifying treat-
ments were administered in the two weeks preceding
the experiments.
The animals were kept in stables of the Clinic for Horses,
University of Veterinary Medicine, Hannover, Foundation,
Schnabel et al. BMC Veterinary Research  (2015) 11:140 Page 2 of 26
housed in standard single boxes on straw or wood shav-
ings under a natural light–dark cycle of German summer
(15–16.3 h of light, sunrise between 05:12 and 05:44, light
from large windows or adjacent paddocks). The horses
were fed hay and concentrates twice a day (at 07:00 and
18:00), according to their body weight, and had access to
water ad libitum. Horses had access to an outdoor 20 ×
60 m sand area once a day, in the late afternoon or early
evening, with a minimum of 2 h rest prior to examination
and sampling.
The horses were allowed to acclimatise for at least 2
days before starting the experiment and were trained by
classical and operant conditioning for blood sampling to
minimise stress during blood collection. Horses stayed in
the clinic for 8 days (t-96 – t72). Examinations were per-
formed and samples were acquired at the horses’ home
stables at day 11 (t264) after treatment (Fig. 1).
Test items and groups
Four horses at a time were kept in the clinic and each
was treated with one of the four different treatments,
A–D. Injection solutions were provided in blinded tubes
in a volume of 1 ml buffered with phosphate-buffered sa-
line (PBS). Treatment letter codes were kept at the DNA
vector manufacturing site and opened only after all study
data had been acquired and evaluated.
Group A received only the transfection reagent (SAINT-
18, Synvolux Therapeutics B.V., Groningen, Netherlands;
containing 6 nmol/ml 1-methyl-4-(cis-9-dioleyl) methyl-
pyridinium-chloride).
Group B received SAINT-18 and linear DNA
vectors (MIDGE-Th1, eqIL12 and IL-1beta receptor
antagonist protein (ILRAP)-eqIL18) encoding equine
IL-12 [NM_001082511.1; NM_001082516.1] and IL-18
[NM_001082512.1] fused to the coding sequence of
the IL-1beta receptor antagonist protein (ILRAP) sig-
nal peptide.
Group C received SAINT-18 and non-expressing MIDGE-
Th1 vector of equine IL-18 with point mutations in all
ATG sequences to delete potential start codons (nonsense
DNA; eqIL18-ATG). These vectors had 1.02 times the
number of total CG sequences, thus, potential CG motifs,
as those given in the dose of group B.
Group D received SAINT-18 and nonsense DNA, simi-
lar to group C, but with inverted CG motifs (eqIL18-
ATG-CG).
DNA vectors
The construction and synthesis of MIDGE-Th1 vectors was
performed by MOLOGEN AG (Berlin, Germany), analo-
gous to the method described by Schirmbeck et al. [21].
Briefly, the expression cassettes containing the cytomegalo
virus immediate-early enhancer/promoter, a chimeric in-
tron, the gene sequence (eqIL12; eqIL18; eqIL18-ATG or
eqIL18-ATG-CG) and the SV40 late protein polyadenyla-
tion site were inserted into the plasmid pMCV1.4. The cod-
ing sequence for the ILRAP signal peptide was fused to the
eqIL18 coding sequence in all eqIL18 MIDGE vectors. A
digestion with the restriction endonuclease Eco31-I (MBI
Fermentas, Vilnius, Lithuania) was performed to set the
expression cassette free. The open ends of the expression
cassette were sealed with loop-forming oligodeoxyribonu-
cleotides, one of them linked to a peptide nuclear localisa-
tion sequence (a peptide with the amino acid sequence
PKKKRKVEDPYC) [21]. Unbound DNA fragments were
degraded with T7 DNA polymerase (MBI Fermentas,
Vilnius, Lithuania) followed by purification of MIDGE-
Th1 vectors.
Formulation of DNA vectors or phosphate-buffered saline
with SAINT-18
The transfection reagent SAINT-18 (0.5 ml dissolved in
water) was vortexed for 1 min and then mixed manually
with 2× PBS (Biochrom AG, Berlin, Germany), or the
DNA was dissolved in 2× PBS, obtaining the test item at a
volume of 1 ml. Lipid-DNA complexes were allowed to
form at room temperature (rt) for approximately 10 min
prior to injection, achieving a mixture of 1 ml in 1× PBS.
MIDGE-Th1/SAINT-18 complexes in groups B, C and D
were formed at a ratio of 1 mg DNA to 0.75 μmol SAINT-
18 and the DNA concentration was 0.4 mg/ml 1× PBS.
Treatment
All time points (t) in the following are reported as h
before or after treatment (t-48 to t264; Fig. 1).





















A SAINT18 11.1 561 2 3 1 4 2 2 4
B SAINT18+ eqIL12 + eqIL18 10.8 589 2 3 1 5 1 2 4
C SAINT18+ eqIL12-ATG + eqIL18-ATG 10.1 548 0 5 1 4 2 2 4
D SAINT18+ eqIL12-ATG-CG + eqIL18-ATG-CG 11.3 591 2 4 0 5 1 2 4
IL interleukin, −ATG nonsense DNA, −ATC-CG nonsense DNA depleted of CG, WBl warmblood, ThB thoroughbred
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The test item dose of 1 ml was split. One half (0.5 ml)
was injected into the pectoralis muscle. The other 0.5 ml
was injected i.d. into the middle third of the neck under
subcutaneous local anaesthesia with 1 ml of lidocaine
(Lidocainhydrochlorid 2 %, Bela-Pharm, Vechta, Germany)
after aseptic preparation of the i.d. injection site with
chlorhexidine (Hibiscrub, tk pharma trade, Hasbergen,
Germany). The i.d. injection site (treat) was marked.
In order to evaluate local effects related to the applica-
tion procedure, but unrelated to the test items at the
time of treatment (t0), the contralateral side of the neck
was treated with 0.5 ml of PBS i.d. (ctrl) after the same
preparation and local anaesthesia as the treat site.
Clipping and shaving of i.d. injection sites was per-
formed at t-36 to allow local irritation to resolve before
injections (t0) and biopsy sampling (t24).
Twenty-four hours prior to treatment (t-24), the
horses were injected with PBS in the same manner, but
contralaterally (0.5 ml i.m. and 1 ml i.d. split into two in-
jections of 0.5 ml each, injected at least 5 cm distant
from each other and 20 cm from the injection sites of
t0; Fig. 1). This injection of PBS was performed in order
to evaluate the systemic effects of the injection proced-
ure unrelated to the test item.
Examinations
The horses underwent a general clinical examination 4
times a day between t-48 and t48 and twice a day during
the rest of their stay.
The skin at the injection sites was also examined clin-
ically at these time points and digital photographs were
taken. Changes were described in the categories oedema,
Fig. 1 Procedure Test procedure illustrated in course of time. The horses were left to acclimatise for at least three days. At t-24, the horses were
injected with PBS (grey symbols) i.m. (0.5 ml) and i.d. (2 × 0.5 ml). Baseline samples (blood) as internal controls for systemic parameters were
acquired from t-48 – t0. At t0, horses were injected with treatments A – D (purple symbols) i.m. (0.5 ml) and i.d. (0.5 ml) and contralaterally with
PBS (grey symbol, 0.5 ml). From t6 – t72, post-treatment samples (blood) of systemic parameters were acquired. At t24, skin biopsies were acquired of
treatment (purple) and PBS control (grey) sites. Eleven days post-treatment (t264), one long-term sample was acquired at the home stable of each
horse. General examinations were performed at all sampling times. Blood samples were used to determine WBC, haemograms, SAA, cytokine mRNA
and ex vivo cytokine secretion by PBMC. Skin samples were used to perform histological examinations, IHC of IL-12, IL-18 and calprotectin, and qPCR of
cytokine and chemokine mRNA
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pain, heat, depigmentation and exudate by a non-linear
scale (0–3 representing absent – high-grade, respect-
ively). Scores were summarised as the sums of all
categories in a single clinical skin score.
Blood samples were drawn at 09:00, 15:00 and 21:00
from t-24–t24, and at 09:00 and 21:00 from t-48– −24
and from t24–t72. One general examination, clinical
scoring of the injection site and blood sampling were
performed on each horse at t264.
Blood sampling
Blood samples were drawn from the jugular vein
after disinfection on the surface area with ethanol,
by use of a vacutainer system (Vacuette, greiner bio-
one, Frickenhausen, Germany) with a 20 G single-use
cannula. Blood was collected in ethylenediaminetetraace-
tate (EDTA)-coated tubes for routine clinical laboratory
measurements, in clot-activator-coated tubes for serum, in
heparinised (sodium-heparin) tubes for the determination
of SAA, and in PAXgene blood tubes (BD, Heidelberg,
Germany) for the isolation of peripheral blood mono-
nuclear cells (PBMC) and for the conservation of total mes-
senger ribonucleic acid (mRNA).
Serum preparation
Blood was allowed to clot at rt for 2 h and was then
centrifuged at 1430 × g for 6 min. Serum without clots
was stored in aliquots at 4 °C for a maximum of 48 h
until further analysis.
Routine clinical laboratory measurements
Analysis by routine clinical laboratory measurements in-
cluded total plasma protein (TPP), haematocrit (Hct),
white blood cell counts (WBC) and differential haemo-
grams, measured by a manual refractometer (TPP), a Sys-
mex kx-21 N (Sysmex Deutschland GmbH, Norderstedt,
Germany) (Hct, WBC) and an ADVIA 120 (Siemens
Healthcare Diagnostics GmbH, Eschborn, Germany)
(haemograms), respectively. Due to the availability of
laboratory devices, differential haemograms were ob-
tained after storage of EDTA-blood at rt for a maximum
of 36 h. Absolute leukocyte subset (neutrophils, lympho-
cytes, monocytes) counts were calculated from percentages
of the ADVIA measurement and total WBC measured im-
mediately after sampling by Sysmex kx-21 N.
Serum amyloid A determination
Serum amyloid A was determined by an immunoturbidi-
metric latex agglutination test (LZ Test Eiken SAA, Eiken
Chemical Co. Ltd., Tokyo, Japan). Limits of detection were
5–300 μg/ml. This assay for human serum amyloid A
(SAA) had been evaluated for horses [34].
Isolation of peripheral blood mononuclear cells
The PBMC were isolated from heparinised blood by
density gradient separation. Briefly, after sedimentation
at rt for 1 h, leukocyte-rich plasma was layered onto
LSM 1077 (density gradient solution, PAA, Pasching,
Austria) and centrifuged (1000 × g, rt, for 30 min). Inter-
phase PBMC were harvested and washed three times in
PBS (500/250/150 × g, rt, 10 min). Cells were counted
using the Cellometer Auto T4 cell-counting system
(Nexcelom Bioscience, Massachusetts, USA).
Cell culture
A total of 2 × 106 PBMC per well were seeded in sterile
cell culture 12-well plates and incubated for 12 h in a
humidified atmosphere at 37 °C (5 % CO2 in air) in 1 ml
culture medium [(Roswell Park Memorial Institute:
RPMI, Biochrom AG, Berlin, Germany) supplemented
with 10 % heat-inactivated foetal calf serum (FCS; PAA
Laboratories GmbH, Pasching, Austria) and penicillin
100 U/ml, streptomycin 0.1 mg/ml (PAA)] (medium
only), supplemented with 1 μg/ml lipopolysaccharide
(LPS; #L2755, Sigma-Aldrich, Munich, Germany)
(LPS-stimulated), or in medium supplemented with
phorbol 12-myristate 13-acetate (PMA; 50 ng/ml) and
ionomycin (1.34 μM) (Cell stimulation cocktail 500×,
eBioscience, Frankfurt, Germany) (PMA/ionomycin-
stimulated). Rather high concentrations of PMA/iono-
mycin were chosen after preliminary experiments (data
not shown) to obtain positive controls of cytokine se-
cretion for each individual.
After incubation, cell-free supernatants were obtained
and stored at −80 °C until further analysis. Thawing was
performed at 37 °C immediately prior to the cytokine
determinations.
Cells in medium only were used to evaluate spontan-
eous cytokine release. Lipopolysaccharide stimulation was
used to evaluate TLR4-response [35] and PMA/ionomycin
stimulation to assess cytokine induction by non-specific
stimulation [36–38] as positive controls.
Determination of equine cytokines in cell culture
supernatants
Tumour necrosis factor alpha was measured in dupli-
cates by a sandwich ELISA for equine TNFα (Duo Set DY
1814, RnD, Wiesbaden, Germany), performed according
to the manufacturer’s protocol with the exception that
coating was carried out at 4 °C overnight, as described
previously [39]. Absorption was measured using a Synergy
2 instrument (BioTek, Bad Friedrichshall, Germany) and
data was analysed by Gene 5 1.11 software (BioTek). The
lower and upper limits of detection of the assay were
31.2–2000 pg/ml. Dilutions of standards and supernatant
samples (if necessary due to exceeding upper detection
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limit) were made with PBS containing 1 % bovine serum
albumin (BSA; # P3688, Sigma-Aldrich).
Two samples (one value from group A at t6; one value
from group C at t24) were excluded from further ana-
lysis as the differences measured between TNFα dupli-
cates were excessive.
Interferon alpha, IFNγ, IL-4, IL-10 and IL-17 were
measured using a bead-based multiplex assay based on
equine-specific monoclonal antibodies on a Luminex
100 System (Luminex, Austin, TX, USA), as validated
previously [40]. Limits of detection were as follows:
IFNα (12–30,000 pg/ml), IFNγ (10–5000 U/ml), IL-4
(40–80,000 pg/ml), IL-10 (15–35,000 pg/ml) and IL-17
(10–10,000 U/ml).
Examination of messenger ribonucleic acid
Preparation of messenger ribonucleic acid from blood
samples
Ribonucleic acid was isolated from whole blood in PAX-
gene blood RNA tubes with the PAXgene blood RNA
Kit (Qiagen GmbH, Hilden, Germany). Isolation was
performed according to the manufacturer’s instruction.
The RNA concentration of the resulting solution was
measured by automated electrophoresis (Experion Sys-
tem, Bio-Rad Laboratories GmbH, Munich, Germany)
using the Experion RNA StdSens Starter Kit (Bio-Rad
Laboratories GmbH), according to the manufacturer’s
instructions.
Preparation of messenger ribonucleic acid of skin
samples
Punch biopsies of 4 mm diameter were transferred into
300 μl RLT buffer (Qiagen GmbH) and homogenised
with TissueLyser II (30 Hz, four times for 5 min each,
Qiagen GmbH). Subsequently, the RNA was extracted
using the RNeasy Fibrous Tissue Mini Kit (Qiagen
GmbH), according to the manufacturer’s instructions.
The resulting RNA solution was used for analysis by
quantitative PCR (qPCR).
Transcription into cDNA
In order to perform the qPCR, 100 ng RNA diluted to a
final volume of 10 μl with DNase/RNase-free water was
transcribed into cDNA. SuperScriptII RT (Invitrogen,
Karlsruhe, Germany) was used in combination with
RNaseOUT Recombinant Ribonuclease Inhibitor (Invi-
trogen), according to the manufacturer’s instructions.
The resulting RNA solutions were stored at −80 °C
and the cDNA solutions at −20 °C.
Standard series for qPCR
Target-specific primers were designed for conventional
and qPCR using the National Centre for Biotechnology
Information primer blast in observance of the Equus
caballus genome, and were produced by Eurofins MWG
Operon, Ebersberg (Table 2). In order to perform the
real-time PCR based on SYBR green, standard dilutions
were produced for absolute quantification of the cDNA
copy numbers.
Ribonucleic acid was eluted from equine liver, uterus
and PBMC by standard procedures using the RNeasy
Plus Mini Kit (Qiagen GmbH). The RNA was reverse
transcribed into cDNA, as described previously.
A conventional PCR was performed with target-
specific primer and Taq DNA Polymerase (5 U/ μl; Invi-
trogen). The reaction mixture had a final volume of
20 μl, consisting of 2 μl of 10× reaction mix, 0.4 μl of
ROTI-MIX PCR 3 (pH 7; Carl Roth GmbH, Karlsruhe,
Germany), 0.6 μl of magnesium chloride (50 mM;
Invitrogen), 0.2 μl Taq DNA Polymerase (5 U/μl; Invi-
trogen), 1.5 μl of forward and 1.5 μl of reverse primer
(5 pmol/μl), 12.8 μl DNase/RNase-free water (Sigma-
Aldrich, Steinheim, Germany) and 1 μl of the cDNA.
All samples were incubated at 95 °C for 10 min
followed by 40 cycles of 30 s at 95 °C, 30 s at 56 °C
and 45 s at 72 °C. Finally, the mixture was incubated
at 72 °C for 10 min and stored at −20 °C.
All samples were analysed on 2.5 % agarose gel with
Gel Loading Dye Blue (0.08 μl/ml; New England Biolabs
GmbH, Frankfurt am Main, Germany) by electrophor-
esis. The rather high agarose concentration was chosen
due to the best separation, as determined in preliminary
experiments (data not shown). When the expected size
was reached, the product was isolated from the gel band
by the QIAEX II Gel Extraction Kit (Qiagen GmbH),
according to the manufacturer’s instructions.
One Shot TOP10 Chemically Competent E. coli (Invi-
trogen) was transformed with the target sequences iso-
lated from the gel bands using the pCR 2.1 TOPO TA
Cloning Kit (Invitrogen). The E. coli solution was trans-
ferred to LB medium (32 g LB agar powder (Lennox;
Carl Roth GmbH) in 1 l Aqua tridest) breeding plates
containing ampicillin (Sigma-Aldrich), 5-Brom-4-chlor-
3-indoxyl-β-D-galactopyranosid (Invitrogen) and Isopro
pyl-β-D-thiogalactopyranosid (Invitrogen). The E. coli
were cultured for at least 24 h at 37 °C. Afterwards,
colonies were transferred into 5 ml liquid LB medium
(20 g LB agar (Lennox; Carl Roth GmbH) in 1 l A. trid-
est.) containing 50 μl ampicillin, and cultured for 16 h at
37 °C and 370 rpm. Subsequently, the plasmids were
isolated from transformed E. coli by the PureLink Quick
Plasmid Miniprep Kit (Invitrogen). The plasmids were
sequenced by Sequence Laboratories Göttingen GmbH
(Göttingen, Germany) to monitor the success of the
transformation. Properly transformed plasmids were
linearised using the restriction enzyme ScaI (Thermo-
Scientific, Schwerte, Germany).
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The concentrations of the resulting solutions were mea-
sured by BioPhotometer (Eppendorf, Hamburg, Germany)
and the copy number per μl was calculated. Finally, solu-
tions with a known concentration of copy numbers were
diluted and used as standard series in the qPCR in
duplicate.
qPCR
Real-time SYBR Green PCR was performed on a StepO
nePlus Real-Time PCR System (Applied Biosystems,
Darmstadt, Germany) with MicroAmp Fast Optical 96-
Well Reaction Plates, 0.1 ml (Applied Biosystems) and
MicroAmp Optical Adhesive Film (Applied Biosystems).
A real-time PCR reaction mixture was used with 12.5 μl
SYBR green (Applied Biosystems), forward and reverse
primers (Table 2) and the addition of DNase/RNase-free
water to achieve a final volume of 25 μl. A volume of
1 μl of sample cDNA solution was added. In order to
quantify the amount of copy numbers, the standard dilu-
tion series produced were used for comparison (102–106
copies/μl). All measurements were performed in dupli-
cate. The samples were denatured for 10 min at 95 °C,
followed by 40 cycles of 15 s at 95 °C and 60 s at 60 °C.
A DNA melting curve analysis was carried out to ensure
the production of a single PCR product.
Skin sampling
Four skin samples were taken 24 h after treatment under
local anaesthesia after aseptic preparation of the skin at
a distance of 1 cm from each injection site. This was the
closest distance possible to achieve four equal biopsy
samples and to still be able to close the sites afterwards
without a high risk of scar formations. Skin biopsy sam-
ples were obtained using 8 mm (for histology) and 4 mm
(for qPCR) diameter biopsy punches (Stiefel, Munich,
Germany). Biopsy sites were closed aseptically by routine
surgical closure.
Punch biopsies for qPCR were snap frozen in 1.5 ml
RNAlater (Ambion, Carlsbad, USA) in liquid nitrogen
and stored at −80 °C until further analysis.
Biopsies for histological examinations were fixed in
4 % neutral buffered formalin [41] for 24 h and then cut
into two halves perpendicular to the surface.
Subsequently, formalin-fixed specimens were rinsed in
slowly running tap-water for 6 h. After this, specimens
were blinded again and embedded in paraffin for storage
at rt until further analysis.
Histology
Sections of the paraffin-embedded tissues were cut (each
3 μm), mounted on glass slides and dried at 60 °C overnight.
Haematoxylin and eosin (H&E) stainings were pre-
pared of each specimen for a general histopathological
examination. One half of each specimen was chosen by
the criteria of lowest artefacts, presence of all layers of
the skin and best plane of cutting (exact sagittal slices
preferred) for further evaluation.
Evaluation
Histopathological alterations were assessed according to
a semi-quantitative score of inflammation (Table 3)
separately in each layer of the skin [epidermis (Ep);
dermis, papillary layer (Dpap) including adnexa; dermis,
reticular layer (Dret); subcutis]. Inflammatory cell pat-
terns were documented and individual cell types were
ranked (0 to 3) according to their proportion of the cell
infiltrate.
Table 3 Histological scores
Score Epithelium Dermis
0 No abnormalities No leukocytes




A few leukocytes, usually
perivascular






3 Some ulcers Many leukocytes, countable




due to overlapping or
high-density masking cell
edges





Descriptions of histological scores for evaluations of epithelium and dermal
layers (papillary and reticular) in skin samples stained with H&E





Forward primer (5'–>3') Forward
primer
volume (μl)






IL12p35 NM_001082511.1 76 GCTGACAGCCATTGACAAGCT 1.5 TTCAAGGGAGGGCTTTTGTG 4.5 0.5
IL12p40 NM_001082516.1 76 TGCTGTTCACAAGCTCAAGTATGA 1.5 GGGTGGGTCTGGTTTGATGA 1.5 0.5
IL18 NM_001082512.1 124 TGCTGGACCAGTAGAAGACA 1.5 AGGTTCAAGCCTGCCAAAGT 1.5 5
IFNγ NM_001081949.1 417 GCTGTGTGCGATTTTGGGTT 1.5 CTCAGGTTAGCTTTGGGCGA 4.5 5
CXCL10 NM_001114940.1 153 GACTCTGAGTGGAACTCAAGGAAT 1.5 GTGGCAATGATCTCAACACG 4.5 5
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Immunohistochemistry
Immunohistochemistry (IHC) was performed on slices
of the half of the formalin-fixed paraffin-embedded skin
samples chosen. Macrophages and neutrophilic granu-
locytes were detected by staining of calprotectin, which
is expressed by these cells [42]. Equine IL-12 and IL-18
were detected by cross-reactive monoclonal antibodies
(mAbs), as described previously [43].
Slices of 3 μm were cut and dried on salined glass slides
(Histobond, Marienfeld, Lauda-Königshofen, Germany) at
60 °C overnight. The sections were deparaffinised in
xylene and rehydrated in a series of alcohols of de-
scending grades. Endogenous peroxidase was blocked
in 0.6 % hydrogen peroxide in 80 % ethanol at rt for
30 min. Sections were rinsed 3 times in PBS at rt for
5 min each.
All the following incubation steps were performed in a
moist chamber. Pretreatment for antigen retrieval was
performed with MAC 387 for optimum results (Table 4).
The sections were incubated with proteinase K (#P2308,
7.0–14.0 U/mg, Sigma Aldrich) diluted in PBS at rt for
30 min. The sections were then rinsed in distilled water
twice at rt for 2 min and once in PBS at rt for 5 min.
The sections were incubated with heat-inactivated nor-
mal goat serum (NGS) diluted 1:5 in PBS for 20 min at
rt to block unspecific protein binding.
The NGS was decanted and the sections were cov-
ered with primary antibodies (Table 4) diluted in PBS
with 1 % BSA and incubated at 4 °C overnight. Negative
controls were incubated with PBS/BSA only. On the
following day, sections were rinsed 3 times in PBS for
5 min at rt (negative controls were handled separately).
The sections were then incubated with biotinylated
secondary antibodies diluted in PBS at rt for 45 min,
followed by rinsing in PBS and signal amplification with
avidin-biotin complex (vector laboratories, Burlingame,
Canada), according to the manufacturer’s instructions
for interleukins, or a ready-to-use kit (IHC Kit, DCS
Immunoline, Hamburg, Germany) was employed, ac-
cording to the manufacturer’s instructions, for calpro-
tectin as a secondary antibody and signal amplification
(Table 4).
After rinsing the sections 3 times in PBS for 5 min,
visualisation was performed with the chromogen, 3-
amino-9-ethylcarbazole (AEC; Peroxidase-Substrat-Kit
AEC, Biologo, Kronshagen, Germany), which was ap-
plied according to the manufacturer’s instructions.
After incubation for 10 min at rt, the slides were rinsed
in PBS for 5 min and in slowly running tap-water for
10 min.
Sections were counterstained in Delafield’s haema-
toxylin for 2 s and rinsed in running tap-water for
10 min to facilitate identification of specific tissue
components.
Slides were mounted with Kaiser’s glycerol gelatine
(Merck, Darmstadt, Germany) and cover-slips and left
to dry at rt.
Sections were viewed with a Zeiss Axioskop (Carl
Zeiss Jena GmbH, Jena, Germany) and images were
digitally captured using an Olympus DP Soft Camera
(Olympus Deutschland GmbH, Hamburg, Germany).
Distinct red staining of cells was interpreted as a
positive reaction of the primary antibodies given that
negative controls showed no such staining. Negative
controls were run in each batch, and isotype controls
and positive controls in other tissues had been per-
formed when establishing the IHC settings used.
Evaluation of immunohistochemistry-stained specimens
Cells stained positive for the respective targets in IHC
were separately evaluated in the different layers of the
skin (Ep, Dpap, Dret). Since only a few specimens con-
tained sufficient amounts of subcutis, this layer was not
assessed further.
Five fields of view (FOV, 0.1435 mm2) with a 20,000 ×
magnification were chosen randomly in Dpap and Dret,
and positively stained cells were counted in images of
these by means of the manual tag function of the Image
Pro programme (Media Cybernetics, Inc., Rockville, MD,
USA). Epithelia were evaluated descriptively.
Statistical analysis
Statistical analysis was performed with SAS Analytics
Pro (SAS Institute Inc., Cary, NC, USA) version 9.3 or
higher. P-values < 0.05 were considered significant.
Cytokine data were log transformed due to log-normal
distribution of the values for statistical comparisons.
Stimulation ratios (times release) were calculated for each
cytokine as cytokine LPS/cytokine medium and cytokine
PMA/ionomycin/cytokine medium.
Determination of baselines as internal controls for
systemic parameters
Analysis of variance (ANOVA) was employed with
time-of-day as a fixed factor and horses as random fac-
tors considering the interaction of time-of-day and
horses for the analysis of the influence of sampling
times on all systemic parameters measured and calcu-
lated before treatment.
For parameters influenced by sampling time, baselines
were calculated separately for each sampling time (09:00,
15:00, 21:00, 03:00) as means of all values measured at
the respective time before treatment. For parameters
independent of sampling time (cytokines in PBMC su-
pernatants), baselines were calculated as means over all
measurements before treatment.
All measurements were evaluated in relation to indi-
vidual baselines. This decision was confirmed by an
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analysis of the influence of baseline values on measure-
ments after treatment in an ANOVA with respect to in-
teractions of treatment and baseline, which showed
significant influences of the baseline measurements.
Influence of treatment on systemic parameters
The influence of the treatments on systemic parameters in
relation to calculated baseline measurements was analysed
by univariate (uv) and multivariate (mv) ANOVA over all
measurements post-treatment. If influences were signifi-
cant in both models, they were considered relevant.
Questionable parameters of treatment effect, judged by
graphic evaluation and ANOVA results, were analysed in
detail for measurements at t12 and t24, SAA as a long-
term indicator, for all sampling times. The influences of
single treatments were analysed by paired t-tests of time-
of-day matched baseline values compared to values at t12
and t24. Comparison of treatment effects of A–D at t12
and t24 was performed by estimated pairwise group differ-
ences with corresponding p-values and 95 % confidence
intervals derived by analysis of covariance (ANCOVA)
methods with baseline as covariate (t-test, baseline ad-
justed), not adjusted for multiplicity.
Influence of treatment on local parameters
The Wilcoxon signed-rank test was employed for clinical
and histological scores to compare treatment and con-
trol sample for each treatment and parameter.
The Kruskal-Wallis test was used to detect overall differ-
ences between treatments employing differences between
treat and ctrl site for individual horses and Wilcoxon
signed-rank test was employed to analyse differences from
0 or comparisons of single treatments.
Data were log transformed for immunohistochemistry
parameters, except for IL-12/IL-18 ratios, and ANOVA
was performed with a Tukey post hoc test to determine
differences between treatments and controls and between
different treatments.
Determination of responders
Parameters statistically significantly affected by treatments
(differences to baseline, t-tests) were used to determine re-
sponders herein. Thresholds and response periods discrim-
inating responders from non-responders were defined by
graphic evaluation of courses of the measurements in each
parameter. Horses were regarded as responders if their
values exceeded the thresholds in at least three parameters.
Responders and parameters with responses exceeding
thresholds were counted for each group.
Influence of treatment on messenger ribonucleic acid
expression
The difference of copy numbers of mRNA in treat (in
blood t12) and ctrl samples (in blood t0) was calculated
for the analysis of mRNA expression in blood and skin
samples. These differences were analysed by Wilcoxon
signed-rank test.
Influences of the horse factors: age, sex, type and colour
Horses of groups which had shown no difference by
treatment on respective parameters were analysed to-
gether for these parameters. The influences of age were
analysed by uv ANOVA. Sex, type and colour influences
were analysed by unpaired t-tests.
Results and discussion
Changes of systemic parameters measured were induced
by DNA containing treatments (B, C, D) and occurred
within 24 h after injection for all parameters measured,
except for SAA, an acute phase protein, which was used
as a long-term indicator demonstrating effects by 72 h
after injection.
In summary, horses showed elevated rectal tempera-
tures (RT) and increased WBC, with the increase mainly
attributable to elevated granulocyte levels, after treatment
with DNA complexed with SAINT-18 (B, C, D). These
effects were interpreted as signs of a mild systemic inflam-
matory reaction [44, 45].
Clinical findings
Treatment with SAINT-18 and MIDGE-Th1 vectors was
well tolerated in all horses. Clinical parameters were
within normal ranges after treatments, except for ele-
vated RT exceeding 38 °C in seven horses. This matches
the findings described for this treatment in horses bear-
ing melanoma [18]. Overall, short-term safety of the
treatment can be assumed.
In comparison to individual time-of-day matched
baselines, the RTs of horses in groups B–D were elevated
between 12 and 18 h after treatments. This difference
reached statistical significance in group B (t-test, p = 0.0467).
However, these elevations of RTs were not significantly dif-
ferent between different treatments (ANCOVA; Fig. 2a).
Rectal temperature increases or development of fever
(RT > 38.5 °C) in the healthy horses included were far less
frequently observed and tended to last for a shorter time
compared to the previous study by Mählmann et al. [18]
of horses affected by melanoma. However, since injection
of MIDGE-Th1 complexed with SAINT-18 coding for lu-
ciferase in five healthy horses had also led to fever in that
study, this difference cannot be easily explained by the
mere presence or absence of melanoma. Further differ-
ences between the studies were the different site of the i.d.
injection (peri-tumorally versus neck) and use of local an-
aesthetics at these sites in the present study. Based on the
present data, the authors cannot exclude that the use of
subcutaneous lidocaine especially may have inhibited the
initial local inflammation at the i.d. injection site and the
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following increase of RT. Other parameters of potential
influence, such as distributions of ages, sexes, breeds and
the seasons of treatments, were not statistically signifi-
cantly different between the previous and the present
study. Hence, the reason for this variance between studies
remains to be elucidated.
Blood counts and haemograms
All haematologic values measured remained within physio-
logical ranges during all observations, with a tendency to-
wards signs of an acute systemic inflammatory response
[45], as follows: WBC increased in comparison to individ-
ual time-of-day matched baselines in horses of groups B, C
Fig. 2 Responses to treatments. a Rectal temperature differences to individual time-of-day matched baselines (BL), (b) Serum Amyloid A (SAA,
absolute concentrations) and (c) Interferon gamma (IFNγ) differences to individual baselines in PBMC supernatants (medium only) are plotted in
histograms for t0 and two measurements post-treatment. Datasets are marked as (group)-(hours post-treatment) at the X-axis. Horizontal bars
represent mean and SD. Grey asterisks (*) represent significant differences from baseline in the respective dataset. Asterisks (*) with brackets (┌ ┌)
represent significantly different comparisons. Group B showed values significantly different from baseline in rectal temperatures at t12 and in IFNγ
at t24. Horses of this group, furthermore, differed significantly from group A in SAA measurements and IFNγ post-treatment
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and D between 12 and 36 h after treatment. Treatment
effects in group B differed statistically significantly from
all other treatments (uv and mv ANOVA, p < 0.05). For
single comparisons, treatment effects on WBC induced
by B and D at t24 were significantly higher than in A
(ANCOVA, p = 0.0494; 0.0227; Fig. 3a).
Neutrophil numbers increased after all treatments, simi-
lar to the WBC effects. The overall effect of treatment on
neutrophil numbers was significant (uv and mv ANOVA,
p < 0.05). However, comparisons of neutrophil numbers to
individual baselines showed statistically significant differ-
ences 24 h after treatment in group B (t-test, p = 0.0406)
Fig. 3 Leucocyte counts. Leucocyte quantities in peripheral blood measured by automated haematology systems are plotted as differences to
individual time-of-day matched baselines (BL) for t0, t12 and t24. Datasets are marked as (group)-(hours post-treatment) at the X-axes. Horizontal
bars represent mean and SD. Grey asterisks (*) represent significant differences from baseline in the respective dataset. Asterisks (*) with brackets
(┌ ┌) represent significantly different comparisons. a Increases of WBC induced by B and D at t24 were significantly higher than in A. b The
increase in neutrophils was significantly different from baseline in B at t24. Group A showed significantly less treatment effects than B, C and D at
t24. c In comparison to individual baselines, lymphocyte numbers decreased significantly after treatment B at t12 and t24, and at t24 in C and D
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only. Group A showed statistically significantly fewer
treatment effects than B, C or D (ANCOVA, p = 0.0167,
0.0497 and 0.0184, respectively; Fig. 3b).
Lymphocyte numbers decreased after treatments B, C
and D. In comparison to individual baselines, lympho-
cyte numbers decreased significantly after treatment B at
t12 and t24 (t-test, p = 0.0399 and 0.0111, respectively),
and after treatments C and D (t-test, p = 0.0005 and
0.0276, respectively) only at t24 (Fig. 3c).
The decrease of lymphocyte numbers after the treat-
ments can be explained in the context of an acute sys-
temic inflammatory state of the horses treated with
DNA, which may occasionally include lymphopenia, as
seen after endotoxin challenge [46]. Decrease in lympho-
cytes and increase in neutrophils has been demonstrated
in mice after systemic administration of complexed plas-
mid DNA paralleling the present findings in horses [47].
Lymphocyte decrease may be due to extravasation fol-
lowing endothelial activation, as indicated by endothelial
swelling and increased perivascular infiltration of lym-
phocytes in histologic sections of skin samples at locally
treated sites in the present study.
Serum Amyloid A
The horses included usually showed physiological levels of
SAA below the lower limit of detection of 5 μg/ml before
treatment. Levels of SAA after treatment were highly vari-
able between individual horses of the same treatment
group. Despite not reaching statistical significance, SAA in
some horses in groups B–D clearly increased 24 to 72 h
after treatment. Group B showed statistically significantly
higher values after treatment compared to group A
(ANOVA uv p = 0.0176; mv p = 0.0197; Fig. 2b).
All horses had SAA levels below 7 μg/ml at t264, ex-
cept for one horse (horse # H), which had shown no in-
crease by t72, but had a history of infectious diseases in
the herd of its home stable to which it returned at t96.
The increase of SAA indicates an acute phase response,
for which it is a sensitive marker in the horse [48]. This
again suggests a systemic inflammatory reaction to the
DNA treatment in individual horses. Most horses in which
SAA increased displayed the rise at t24, but maximums
were usually reached at t48 or t72. Serum Amyloid A is
known to rise 6 to 12 h after surgery or experimental in-
flammation and to peak after 48 or even 72 h [34, 49, 50].
This matches the present findings, but may also be due to
prolonged response or secondary mechanisms in response
to treatments with MIDGE-Th1 vectors, which are detect-
able long-term after application [51]. Furthermore, biopsy
sampling at t24 may have contributed to the acute phase
response of the horses. The reaction affecting SAA, how-
ever, seems to resolve in a short time, as measurements at
t264 no longer displayed increased values.
Cytokine messenger ribonucleic acid in blood samples
Cytokine expression in peripheral blood samples, deter-
mined by qPCR, was not significantly altered between con-
trols (t0) and treatment (t12) in any treatment group or
between different treatments. Interferon γ transcripts could
not be detected at all in peripheral blood (Additional file 1:
Table S1). Insufficient sensitivity of the qPCR assay for
IFNγ may be assumed, as its absence is contrary to the
detection of IFNγ protein. Analysis of mRNA in blood at
t12 had been chosen as the horses in the previous study
[18] had developed fever 12 to 18 h post-treatment and,
thus, systemic effects on mRNA around these time points
were expected to be noticed as well. The examination of
more time points would be warranted in future studies to
track the dynamics of cytokine expressions and to identify
later changes.
Equine cytokines in cell culture supernatants
Cytokines were usually detectable by enzyme-linked im-
munosorbent assay (ELISA) or bead-based assay in super-
natants of ex vivo-cultured PBMC (with and without
stimuli) and displayed great interindividual variances.
Interferon-α was hardly detectable, even after stimulation,
and was, thus, excluded from further analysis (Additional
file 2: Table S2).
There were no treatment effects detected in individual
concentrations and alterations of IL-4 and IL-17 in su-
pernatants of cells cultured without stimuli compared to
individual baselines.
Stimulation ratios (e.g. IFNγ PMA-ionomycin/IFNγ medium)
showed high interindividual variances in all cytokines,
but no treatment effects were observed.
Tumour necrosis factor alpha (TNFα, in medium only)
increased in single horses of all treatment groups com-
pared to individual baselines. Ex vivo LPS stimulation of
TNFα secretion was mild (mean stimulation ratio = 3.717
times secretion). Changes post-treatment were usually
similar in medium and LPS settings. The increase of TNFα
after treatments was statistically significant in groups B, C
and D. Treatment effects in groups C and D were higher
than in A (details given in Fig. 4).
Within 24 h after treatment, levels of IFNγ increased
(without ex vivo stimuli) only in group B to a mean value
statistically significant from group A. Four out of six
horses in group B displayed an increase of IFNγ (Fig. 1c).
Lipopolysaccharide stimulation of PBMC ex vivo re-
sulted in only mild induction of IFNγ (mean stimulation
ratio = 2.041 times secretion). Changes after treatments
were similar to those in medium settings, but did not
reach statistical significance.
Interleukin-10 in medium settings decreased at t6 after
treatment B and at t12 after all other treatments. In gen-
eral, LPS mildly induced IL-10 secretion ex vivo (mean
stimulation ratio = 2.821 times secretion). The stimulated
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IL-10 secretion in PMA and ionomycin settings decreased
at t12 in groups B, C and D (Fig. 5).
Detection of cytokine effects proved challenging, as
the variance of ex vivo cytokine release was high even
before treatments. This variance in immune parameters
is not unexpected in outbred species such as the horse
[52, 53]. However, in comparison to individual baselines,
increases of TNFα and IFNγ proteins were systemically
induced by treatment with MIDGE-Th1/SAINT-18 (B, C
and D), while IL-10 synthesis tended to decrease. These
Fig. 4 Tumour necrosis factor alpha. Tumour necrosis factor alpha differences to individual baselines in PBMC supernatants measured by ELISA
are plotted for releases (a) in medium only, (b) after LPS stimulation and (c) after PMA/ionomycin stimulation for t0, t12 and t24. Datasets are
marked as (group)-(hours post-treatment) at the X-axes. Horizontal bars represent mean and SD. Grey asterisks (*) represent significant differences
from baseline in the respective dataset. Asterisks (*) with brackets (┌ ┌) represent significantly different comparisons. The increase of TNFα could
be statistically noticed in B (t12, medium and LPS), in C (t12, LPS) and in D (t24, medium and LPS). Treatment effects after LPS stimulation at t12
in C or D were higher than in A. Treatments containing DNA (B – D) induced higher TNFα secretion than transfection reagent alone (A)
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changes after each treatment containing DNA indicate a
bias towards a pro-inflammatory immune state [54–58].
It was intended to confirm this at the mRNA level of
whole blood leukocytes. However, the qPCR used here
was possibly not sensitive enough to detect low numbers
of mRNA copies, which may, nevertheless, have been re-
peatedly translated to detectable amounts of cytokine
proteins.
Fig. 5 Interleukin 10. Interleukin 10 differences to individual baselines in PBMC supernatants measured by a bead-based assay are plotted for
releases (a) in medium only, (b) after LPS stimulation and (c) after PMA/ionomycin stimulation. Data presented at t0, t12 and t24. Datasets are
marked as (group)-(hours post-treatment) at the X-axes. Horizontal bars represent mean and SD. Asterisks (*) with brackets (┌ ┌) represent significantly
different comparisons. Interleukin 10 decreased after all treatments. Treatment effects after LPS stimulation (b) in group D at t24 (increase) differed
significantly from those in A, B and C. After PMA and ionomycin stimulation, treatment effects in C (decrease) differed significantly from those in a
(near baseline) at t12. The greatest interindividual variances were seen in group b
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Systemic effects of DNA treatment
According to the evaluations of systemic parameters in
the present study (RT, haemograms, SAA, cytokines in
PBMC supernatants), simultaneous i.m. and i.d. treat-
ment with DNA complexed with cationic lipid provokes
a systemic immune reaction in horses in accordance
with previous reports on inflammation induced by the
combination of DNA and cationic transfection reagent
in mice [59, 60]. The inflammatory response herein was
shown to be independent of transgene expression or CG
motif content of the DNA injected, as differences
between groups B and D were usually not statistically
significant. It could, therefore, be hypothesised that this
stimulation of the immune system may be responsible
for parts of the antimetastatic effects demonstrated by
Mählmann et al. [18] due to subtle modifications of the
immune system induced by this antigen-unspecific modu-
lation. However, plasmids containing nonsense DNA
alone were not effective in melanoma therapy in previous
studies in horses [7, 8], indicating that not just any DNA
can be assumed to be effective and complexation with a
cationic lipid might be required.
Although most of the recent literature on DNA ef-
fects focuses on the immunological effects of CG motifs
[26, 61–63], in vivo application of complexed DNA
herein induced systemic and local effects independent of
the CG motif content. It should be mentioned that the
CG motif contents of the vectors have been estimated on
the basis of counting CG without analysis of the flanking
sequences. A detailed analysis was not possible as infor-
mation on the exact sequences of stimulatory motifs or
their allocation to classes are only known for a few oligo-
deoxynucleotides in the horse [53, 62, 64] and have yet
not been completely recognised. In comparison to plas-
mids, which often carry CG motifs in the backbone,
MIDGE vectors only contain CG motifs in their expres-
sion cassettes [20, 65]. According to the rather low CG
motif content in the MIDGE-Th1 vectors utilised and the
absence of statistically significant differences of treatment
effects between DNA containing CG and depleted of CG,
the authors conclude that signalling via TLR-9 receptors is
probably not the primary mechanism of immunostimula-
tory action of in vivo applied complexed MIDGE-Th1 vec-
tors in horses.
Non-nuclear DNA, independent of CG motif and TLR
signalling, stimulates innate immune responses, such as
pro-inflammatory cytokine production via different path-
ways, as described more recently [30–33]. The signalling
cascades employed are induced by intracellular double-
stranded DNA and usually involve cGAS (cyclic GMP-
AMP synthase) and STING (stimulator of IFN genes),
AIM2 (absent in melanoma 2) and inflammasome activa-
tion or ribonucleic acid (RNA) polymerase III and RIG-I
(retinoic acid-inducible gene), leading to pro-inflammatory
and antiviral immune responses [29, 31, 32]. To the best of
the authors’ knowledge, there are no reports of these
mechanisms in horses. However, due to their high phylo-
genetical conservation, they are very likely to exist in
horses as well. Thus, although the causative molecular
mechanism of the systemic and local immunostimulatory
effect independent of the CG motif content of the DNA
herein cannot be identified based on the present data, the
stimulation of the pathways of the innate immune system
by complexed DNA reaching cytosolic compartments de-
scribed seems likely.
Responder classification in systemic effects of treatments
The parameters included for responder classification were
RT, SAA, neutrophil and lymphocyte counts, TNFα release
in response to LPS stimulation and IFNγ release from un-
stimulated cells (medium only). White blood cell counts,
although influenced by treatments, were not included, as
this parameter is dependent on neutrophil and lymphocyte
counts which were already being considered. Response pe-
riods up to t24 were usually chosen, except for SAA (until
t72; Table 5). A classification into responders and non-
responders was not performed for local parameters evalu-
ated in skin samples because it was not possible to define
threshold values by visual inspection due to the lack of
graphical dichotomy of the values measured.
Responders were found in all groups. There were no
noteworthy changes of SAA, neutrophil counts or IFNγ in
group A. In groups B–D, there were more responses than
in A, but no clear differences between types of DNA.
Interestingly, not a single grey horse was classified as a re-
sponder after treatment with complexed DNA (B, C or D;
Table 5).
While some horses displayed systemic effects following
DNA application (usually in RT, haematological parame-
ters, acute phase proteins and cytokine secretion), others
showed no effects at all. Similar to findings in melanoma
patients, responders and non-responders to DNA treat-
ment seem to exist in healthy horses. In accordance with
single parameters of systemic evaluations, significant dif-
ferences between expressing (B) and non-expressing (C)
or CG motif-free non-expressing (D) DNA could not be
found by the responder classification.
Since no grey horse was classified as a responder, the
authors cannot conclude reasonably on the predictive
value of the parameters, thresholds and response periods
chosen for the responder classification or on anti-
tumour effects in grey horses bearing melanomas.
Evaluation of local treatment effects in clinical and
histological examinations
The skin was unaffected and clinical scores were usually
classified as grade 0 before treatment. Treatment (A–D
injected i.d. locally treated skin samples: treat) and control
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Table 5 Responders in systemic parameters
Treatment group / horses A) # A # E # I # N # R # W B) # B # F # K # S # O # X C) # C # G # L # P # U # Y D) # D # H # M # Q # V # Z
Age (years) (groups: mean) 11.1 21 4 11 8 13 9 10.6 5 17 19 7 5 10 10.3 2 8 11 8 20 11 10.9 8 8 10 14 17 8
Sex fe fe mc mc mc mi fe mc mc fe mc mi mc mc mc mc mc mi fe fe mc mc mc mc
Type ThB WBl WBl WBl WBl ThB ThB WBl WBl WBl WBl WBl ThB WBl WBl WBl WBl ThB ThB WBl WBl WBl WBl WBl
Colour g g o o o o g o o o o g g o g o o o o g o o g o
Para-meter Thre-shold Period (h)
SAA (μg/ml) 10 72 0 − − − − − − 3 − − + + + − 3 − − + − + + 2 + − − − − +
RT (°C)a 0.5 24 3 + + − − + − 3 − − + + + − 3 + − − − + + 5 + + + + − +
Neu (G/l)a 1 24 0 − − − − − − 3 + − − + + − 2 − − − − + + 2 + − − − − +
Lymph (G/l)a -0.4 24 1 + − − − − − 4 − − + + + + 2 − − − − + + 5 + + + + − +
TNFα (pg/ml)b,
LPS
5000 24 2 + − + − − − 3 − − + + + − 3 − − + − + + 4 + − + + − +
IFNγ (U/ml)b, med 20 24 0 − − − − − − 3 + − + − − + 1 − − − − − + 2 + − − − − +
Responder 1 + − − − − − 3 − − + + + − 2 − − − − + + 4 + − + + − +
Responses/group parameters with
response
6 3 1 1 0 1 0 19 2 0 5 5 5 2 17 1 0 2 0 5 6 20 6 1 3 3 0 6
Numbers of horses that display values of ≥ threshold given in each cell of group columns; response present (+, threshold reached) or absent (−, threshold not reached) given in each cell of individual horses (IDs)
fe female, mare, mc male castrated, gelding, mi male intact, stallion, Wbl Warmblood, ThB thoroughbred, g grey, o other (non-grey), WBC white blood cell counts, Neu neutrophil counts, Lymph lymphocyte counts, med
medium settings, LPS LPS settings, responder (response + in min. 3 parameters), response in groups at least two horses +
adifferences to individual time-of-day matched baselines











(PBS injected i.d. control skin samples: ctrl) sites showed
mild oedema (grade 1–2) after treatments. Other alter-
ations were very rare (painfulness: n = 2 in treat and ctrl;
redness n = 2 in treat and ctrl; depigmentation = 2 in ctrl
and treat). Clinical scores were not statistically different
between control and treatment sites or between different
treatments.
The evaluation of skin biopsies stained with H&E re-
vealed ulceration of the epithelia (Additional file 3a–c) and
perivascular mixed-cell dermatitis with some additional in-
filtrating leukocytes in a diffuse pattern, especially in the
Dret. Inflammatory cells were predominantly of lymphoid
origin. Macrophages appeared perivascularly in subepithe-
lial positions proximate to most ulcers and infrequently in
diffuse patterns. Neutrophilic granulocytes were randomly
seen intravascularly and sometimes found perivascularly
and abundantly in a diffuse pattern in higher grade inflam-
mation in Dret (Additional files 3a, c and 4a–c).
Scores of inflammation did not differ significantly
between treatments and controls or between different
treatments in any layer.
Shaving of the skin was performed to optimise the cut-
ting of histological slices of biopsy samples after fixation,
as hairs often cause disruption of slices and artefacts in
microscopic views. An early time point (t-72) was chosen
for shaving to facilitate gross recovery before treatment.
Shaving and scrubbing alone led to ulcerative inflammation
of the epithelium visible in histologic slides, as shown in
six additional healthy horses which underwent shaving and
scrubbing without further treatment (Additional file 5).
This preparation of the skin may have hidden treatment ef-
fects on epithelia, but not on deeper skin layers where the
main alterations in response to treatments A–D were ex-
pected. However, shaving immediately prior to taking biop-
sies might have been better. Nevertheless, since the effect
of DNA was noted mainly in the dermis, this aspect of the
study design may not be of relevance for interpretation of
the data.
Local anaesthesia was performed at the i.d. injection
sites due to ethical reasons, to facilitate secure intrader-
mal application without complication by defensive ac-
tions of the horses and to avoid the need for sedation, as
this could have influenced parameters characterizing the
systemic immune response. The volume applied is likely
to have contributed to the oedema observed. It is, fur-
thermore, possible that the application of local anaes-
thetics at the i.d. injection sites influenced the immune
response to the treatments applied. Local anaesthetics
are known to have anti-inflammatory properties [66]
and could, thus, have inhibited the inflammatory re-
sponse. The lidocaine used was applied subcutaneously.
Its anaesthetic action is thought to last a maximum of
three hours after subcutaneous infiltration [67], allowing
the assumption that the majority of the substance should
then be cleared from the injection site. MIDGE-Th1
DNA applied intradermally has been described to stay in
the dermis long-term, thus, the authors assume that the
potential anti-inflammatory effect of lidocaine did not
mask the effects of the treatments completely. It still
cannot be excluded that local anaesthesia partially influ-
enced the immune response to DNA/SAINT-18.
Immunohistochemistry results in the skin
Calprotectin stained by MAC387
The strata spinosum, granulosum and lucidum, and hairs’
epithelial sheaths of the stratified squamous epithelium in
all specimens were generally immunopositive for calprotec-
tin. Ulcers in the epithelium usually did not stain, except
for single infiltrated cells or debris (Additional file 6a, c).
Calprotectin positive cells in the dermis were frequent in
perivascular locations, but also occurred infrequently in
other localisations in a diffuse pattern (Additional files 6b–
d and 7a, c). Calprotectin, detected by MAC 387, is a
marker for myeloid cells [68] and for epithelial stress [69].
The immunohistochemical staining pattern observed in
the present skin samples corresponded well with neutro-
philic granulocytes and macrophages identified by H&E
staining.
Overall, treat specimens contained more calprotectin-
positive cells than ctrls in both layers. For single com-
parisons, this was significant in the Dret in A (Aa) and B
(Bb). The ctrl samples of B, C and D contained more
calprotectin-positive cells than ctrl samples of A without
reaching significance. In the Dret, the treat samples of B
contained statistically significantly more calprotectin-
positive cells than the treat samples of A (details given
in Fig. 6a, b).
Myeloid cell infiltration reveals that inflammation was in-
duced in both the treat and ctrl samples. Thus, an acute in-
flammatory response was induced locally by i.d. injections
in general, and by the transfection reagent, SAINT-18,
which induced an influx of leukocytes and expression of
the cytokines IL-12 and IL-18 (see below). The addition of
DNA tended to enhance the inflammatory response, with-
out reaching statistical significance by means of inflamma-
tion scores and IHC evaluation. This may be due to the
overlapping of the systemic effects causing increased tissue
reactivity and effects of the local stimulus by, for example,
the pressure of the injection demonstrated in ctrl sites.
The treatment schedule closely resembled that of the
previous study by Mählmann et al. [18]. The i.m. and i.d.
administered portions of the treatments were carried out
simultaneously. Therefore, it is not possible to distin-
guish their contribution to the systemic effects. However,
the impact of the route of administration on systemic ef-
fects is an interesting aspect that warrants investigation
in future studies, considering the routes used and, for
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example, transdermal application methods used for DNA
vaccines [70, 71].
Local expression of IL-12 and IL-18 proteins in skin
samples after treatment
The IL-12 and IL-18 proteins were stained by monoclo-
nal antibodies in IHC for the investigation of transgene
expression.
In general, IL-12 and IL-18 were present in the same tis-
sues and cell types in skin samples of the sites treated and
of healthy control animals: squamous epithelium, hairs,
glands (sebaceous and apocrine), fibrocytes, endothelia
(unstained in some bigger vessels), pericytes, muscle cells,
nerves (in parts) and leukocytes (Additional files 8, 9, 10,
11, 12 and 13). However, intensity varied, and some cell
types (e.g. inflammatory cells) were present more fre-
quently in samples after treatment, resulting in a theoret-
ically higher amount of locally available IL-12 and IL-18.
The treat samples contained more IL-12 positive cells
than the ctrls. This was statistically significant for single
comparisons in treatments A and B in both layers, Dpap
and Dret. Furthermore, the Dret ctrls contained signifi-
cantly fewer IL-12-positive cells in A than the Dret ctrls in
D. The treat samples did not differ statistically signifi-
cantly between different treatments in the absolute num-
bers of IL-12-positive cells in any layer (details given in
Fig. 6c, d ).
There was no statistically significant overall difference in
the IL-18-positive cells in the Dpap between treat and ctrl.
The Dpap ctrls contained statistically significantly fewer
IL-18-positive cells in A than in C. The treat samples in
Dret contained more IL-18-positive cells overall than the
ctrls. This was statistically significant in A. The treat sam-
ples did not differ statistically significantly between differ-
ent groups in the numbers of IL-18-positive cells (details
given in Fig. 6e, f ).
Cytokine and chemokine mRNA in skin biopsies
For further investigation of in vivo expression of recombin-
ant IL-12 and IL-18, IL-12 and IL-18 mRNA were measured
Fig. 6 Immunohistochemistry results. Mean positive cells per FOV are plotted for the papillary dermis (Dpap, top) and the reticular dermis (Dret,
bottom) for each treatment (A – D) and site (Ctrl: control; treat: local treatment) for calprotectin (a, b), Interleukin (IL)12 (c, d) and IL-18
(e, f) determined by immunohistochemistry. Median, quartiles, minimum and maximum plotted for each dataset. Asterisks (*) with brackets
(┌ ┌) and same letters (Aa, Bb) represent significantly different comparisons. Treat samples overall contained significantly more calprotectin-positive
cells and IL-12 positive cells than ctrls in the Dpap (a), and Dret (b). For single comparisons, this was significant in Dret (b) in treatment groups A (Aa)
and B (Bb). Control samples of A had significantly fewer calprotectin-, IL-18- and IL-12-positive cells than those of other treatment groups. Treat samples
of B contained significantly more calprotectin-positive cells in Dret than those of A (*)
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in skin biopsies by SYBR green qPCR. Furthermore, in
order to confirm these and their biologic activity, in
addition to the interleukins, the downstream mediator typ-
ically induced by IL-12, IFNγ [7] was analysed, as well as a
chemokine strongly induced by the latter, CXCL-10 [68]
(Additional file 1: Table S1).
The detection of IL-12 expression by qPCR was ham-
pered by the interference of MIDGE- Th1 DNA in the
(treat) samples, as MIDGE-Th1 vectors present at the site
of injection could not be digested completely prior to re-
verse transcription of mRNA into cDNA (complementary
DNA), and PCR primers could not be designed to dis-
criminate between equine recombinant IL-12 transcripts
expressed by MIDGE-Th1 vectors and endogenous IL-12
transcripts. Consequently, measurement of IL-12 by qPCR
always resulted in positive results and discrimination from
false-positive results was not possible.
Copy number differences between treat and ctrl samples
of IL-18 were lowest in group A, which varied statistically
significantly from B to D (Fig. 7a).
Copy number differences of CXCL-10 between treat and
ctrl of individual horses were statistically significantly
lower in group A compared to the other groups. Group B,
furthermore, showed statistically significantly higher dif-
ferences of CXCL-10 mRNA copy numbers between ctrl
and treat than the other groups treated with complexed
DNA (C or D) (Fig. 7b).
Similar to the blood samples, IFNγ mRNA/cDNA was
not detected at all. For IHC, unfortunately, no antibody
was available to detect IFNγ protein in comparison.
Again, insufficient sensitivity of the qPCR assay for IFNγ
mRNA/cDNA detection cannot be excluded, as the re-
sult on IFNγ mRNA levels is contrary to the significant
detection of CXCL-10.
Transgene expression
In vitro transgene expression after transfection of mam-
malian cells with MIDGE-Th1 eqIL12 and eqIL18 was
proven on the mRNA level [18] and in vivo transfection
of MIDGE-Th1 vectors was generally confirmed in other
species, e.g. in rats, on the protein level as well [72].
Although expression of recombinant IL-12 and IL-18
in group B could not be verified directly by detection of
IL-12 and IL-18 transcripts, the mRNA of CXCL-10, a
downstream mediator of IL-12 and IFNγ [73, 74], was
significantly elevated in skin samples treated with ex-
pressing MIDGE-Th1 (group B, treat). As it has been
shown that effects on downstream mediators are ampli-
fied due to enhancing loops [74], CXCL-10 mRNA could
be detected even if recombinant IL-12 and IL-18, and
IFNγ induced by these, are not detectably increased. As
CXCL-10 has been shown to be produced after intratu-
moural injection of IL-12 plasmids in human melanoma
[75], subsequent to IFNγ after IL-12 treatment in mice
[74] and after transfection of B16 melanoma with IL-18,
also in mice [76], it is likely that CXCL-10 is a relevant
anti-tumour mediator in melanoma immunotherapy
with IL-12/IL-18 DNA also in horses.
Treatment with DNA complexed with SAINT-18 did
not lead to vast amounts of cytokines being released by
PBMC or expressed by blood leukocytes. The IL-12 and
IL-18 expression levels were not increased in blood cells
Fig. 7 Treatment effects on messenger ribonucleic acid expression in the skin. The treat-ctrl differences of copy numbers of IL-18 (a) and CXCL-10
(b) measured by qPCR in skin samples are shown in histograms. Horizontal bars represent medians and ranges. Asterisks (*) with brackets (┌ ┌)
represent significantly different comparisons. The expressions of IL-18 increased by local treatment in comparison to ctrls in groups B – D. The
expression of CXCL-10 in skin biopsies of the treat site was significantly higher overall than in the ctrl samples in all treatment groups. The treat-ctrl
difference (b) of copy numbers examined was significantly lower in A than in the other treatment groups. Group B, furthermore, displayed significantly
higher treat-ctrl differences of CXCL-10 copy numbers than C or D
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after treatments and IL-12 protein could not be detected
by a bead-based assay (validated in horses previously
[77]) in PBMC supernatants, even after stimulation as
evaluated in samples of eight horses of groups A–D, in-
cluding four responders (data not shown). It can be con-
cluded that circulating leukocytes and tissues influencing
these were not transfected to a great extent by express-
ing DNA vectors, as recombinant IL-12 and IL-18 were
not statistically significantly elevated in post-treatment
blood samples of B and only a moderate increase in the
production of IFNγ protein was detected as an induced
downstream cytokine of IL-12 and IL-18 [14–16].
However, local treatment with DNA expressing IL-12
and IL-18 (B) induced an increase in IL-12-positive cells
in the dermis in comparison to PBS controls. This could
be due to local transfection of cells or to induction of
endogenous IL-12. This cannot be discriminated herein
by means of IHC.
Influences of horse factors on treatment effects
The authors noted great interindividual variances in treat-
ment effects on most parameters. The following possible
influencing factors were evaluated to elucidate the origin
of these variances: age, sex (mares vs. geldings; two stal-
lions were excluded from analysis due to limited number),
type (breed) and colour of coat.
As treatment differences were usually observed between
treatment with (groups B, C and D) and without DNA
(group A), horses of groups B, C and D were combined
for the analysis of influences on treatment effects.
Mares showed higher increases in WBC (t-test, p= 0.0068)
and neutrophils (t-test, p = 0.0282), and higher TNFα re-
sponses (medium settings; t-test, p = 0.0172) than geldings
(Additional file 14). This is in accordance with the finding
of higher plasma levels of TNFα in healthy mares [78] and
the authors’ finding of a rather pro-inflammatory tendency
of mares compared to geldings when analysing baseline
measurements prior to treatments [79].
Thoroughbred type horses showed higher TNFα re-
sponses (medium settings; t-test, p = 0.0240) than WBl type
horses (Additional file 14). The breed has previously been
shown to influence the cytokine response in TNFα to in
vivo stimuli [80], but this has not yet been investigated for
DNA treatment. The allocation of different breeds to the
types of WBl and ThB in the present study may be arbi-
trary to some degree and does not necessarily represent
Fig. 8 Influence of colour. The results of horses treated with DNA (groups B – D) are summarized. Differences of (a) lymphocytes and (b) TNFα
release after LPS stimulation to individual baselines calculated at t12 and t24 are plotted in histograms for grey horses (grey) and horses of other
colours (other). Calprotectin-positive cells in five fields of view (FOV) are plotted (c) for the papillary dermis (Dpap), and (d) the reticular dermis
(Dret) in histograms for PBS ctrl and treat sites. Horizontal bars represent mean and SD. Asterisks (*) with brackets (┐ ┐) represent significantly
different comparisons. Lymphocyte decreases (a) to individual time-of-day matched baselines were significantly less in grey than in other horses.
The TNFα increases to individual baselines in PBMC supernatants were significantly lower in grey than in other horses. Significantly fewer
calprotectin-positive cells were found in the Dret (b) of treat sites of grey horses than in samples of non-grey (other) horses
Schnabel et al. BMC Veterinary Research  (2015) 11:140 Page 21 of 26
biological dichotomy. Thus, this limitation should be
considered for the judgement of its influence.
Sex and type are known to influence immunological
parameters [80–84] and to find such effects herein was
not unexpected. As the treatment groups of horses were
balanced with respect to these horse parameters, bias of
the interpretation of the results concerning treatment ef-
fects is not likely.
In addition, there was a relation between the coat
colour of the horses and their responses to treatment
with DNA. Grey horses showed statistically significantly
fewer lymphocyte decreases than horses of other colours
(t-test, p = 0.0037) and fewer increases of ex vivo se-
creted TNFα in response to stimulation with LPS (t-test,
p = 0.0470; Fig. 8). Statistically significantly fewer myeloid
(calprotectin-, MAC-387-positive) cells were found (t-test,
p = 0.0413; Fig. 8) in the Dret of treat samples of grey
horses than of non-grey horses, resulting in statistically
significantly lower treat-ctrl differences (t-test, p = 0.0379).
Furthermore, none of the grey horses included was
classified as a responder to DNA treatment with regard
to systemic parameters. Therefore, the acute immune re-
action of grey horses to DNA treatment seems to be
milder than that of non-grey horses as defined by the
parameters included in the present report. Some differ-
ences between grey and non-grey horses in immuno-
logical parameters reported previously, such as different
associations of microsatellites and single nucleotide poly-
morphisms with immune responses to Equine Herpes Virus
vaccination [85], match the findings of different immune
reactivity reported herein. The milder response of grey
horses to DNA complexed with transfection reagent may
require stronger stimulation in DNA vaccination, as inflam-
mation enhances DNA uptake and antigen processing [86].
It might even be speculated whether this different
acute immunological response contributes to melanoma
development in grey horses, as genetic bases of grey coat
colour are proposed to have an influence on other organ
systems, including cell cycle regulation and immune
functions [87–89], which may affect tumour develop-
ment and immune escape. This is speculative based on
the present data of healthy horses, but certainly warrants
further investigation.
Conclusions
Treatment with DNA complexed with the transfection
reagent SAINT-18 is immunostimulatory in healthy
horses, independent of transgene expression and CG
motif content. Grey horses and horses of other colours
differ in their systemic and local acute immune reaction
to treatment with linear DNA vectors complexed with a
cationic lipid. Grey horses seem to be non-responders
with respect to non-specific systemic effects of DNA. It
cannot be excluded that this characteristic of grey horses
may be related to the development of melanoma. Further
research elucidating this issue is warranted.
Additional files
Additional file 1: Table S1. Cytokine cDNA copy numbers (qPCR).
Equine cytokine expression measured with absolute quantification by
qPCR after transferring mRNA into cDNA. Medians of copy numbers
given per μl; t0: before treatment; t12: 12 h after treatment; ctrl: local PBS
control sample; treat: locally treated (A–D) sample; n.d. = not detectable
(<100 cDNA copies/μl).2
Additional file 2: Table S2. Ex vivo secreted cytokines. Equine cytokines
in PBMC supernatants after 12 h of cell culture: mean concentration (STD);
BL: Baseline (mean t-24–t0); t12: 12 h post-treatment; t24: 24 h post-treatment;
Detection limits: IFNα (12–30,000 pg/ml), TNFα (31.2–2000 pg/ml), IFNγ
(10–5000 U/ml), IL-4 (40–80,000 pg/ml), IL-10 (15–35,000 pg/ml), and
IL-17 (10–10,000 U/ml).
Additional file 3: Histology of epithelia and papillary dermis.
Illustration of findings in representative skin samples (H&E
staining). Evaluation was performed for single layers: epithelium (Ep),
papillary dermis (Dpap), reticular dermis (Dret). a) Overview of Ep with
two ulcers (arrows) and areas of subepithelial infiltration. Note beginning
of ulceration in two additional localisations (dashed arrows). b) Detail of
Ep with ulceration (magnification of frame in A). Note cell debris in ulcer
(arrow) and subepithelial infiltration of leukocytes (arrowhead) in Dpap.c)
Inflammation in Dpap with adnexa. Distinct infiltration of leukocytes in
perivascular localisations (asterisks), while only a few leukocytes are
present in a diffuse distribution pattern in other areas.
Additional file 4: Histology of the reticular dermis. Illustration of
findings in representative skin samples (H&E staining) in Dret.
a) Overview of Dret with haemorrhage (arrows). b) Detail of Dret with
haemorrhage (magnification of A). Note haemorrhage (arrows) and
massive perivascular infiltration of leukocytes (asterisks). c) Detail of
inflammation in Dret. Distinct infiltration of leukocytes in perivascular
(asterisks) and intravascular (arrowheads) localisation, while only a few
leukocytes are present in a diffuse distribution pattern in other areas.
Additional file 5: Evaluation of shaving and scrubbing effects on
skin irritation. Description of an additional experiment to evaluate the
impact of shaving and scrubbing on skin alterations.
Additional file 6: Immunohistochemistry for calprotectin.
Immunohistochemical localisation of calprotectin (red) in
representative skin samples (counterstained with haematoxylin).
a) Overview of Ep and Dermis with low grade inflammation. Calprotectin-
positive cells are present in Dpap (arrows). In addition, Ep and hairs were
immunopositive in parts. b) Overview of Dret with haemorrhage (arrows).
Some leukocytes (asterisks) near and within haemorrhage stained positive
for calprotectin (red). c) Epithelial Ulcer (arrow). Subepithelial leukocytes
frequently stained calprotectin-positive (red). In addition, parts of the Ep
(Str. spinosum and Str. granulosum) are positive for calprotectin. d) Dpap
with adnexa. Infiltrating calprotectin-positive (red) leukocytes in perivascular
localisation indicate a distinct inflammation. Hairs (H) and excretory ducts of
apocrine glands (G) were negative.
Additional file 7: Detail of calprotectin immunohistochemistry
(continued). Immunohistochemical localisation of calprotectin (red) in
representative skin samples (counterstained with haematoxylin), a) Dret
with perivascular inflammation around larger vessels. Detail of large artery
(A) and vein (V), which are surrounded by multiple calprotectin-positive
(red) leukocytes. b) Dret – Isotype control. Similar localisation as a) with
large artery (A) and smaller veins (V), where a perivascular infiltration
(asterisks) is visible, but red staining is absent (negative). c) Perineural
leukocyte infiltration in Dret. Detail of nerve (N) and vessels; note the
distinct perivascular and perineural infiltration with calprotectin-positive
leukocytes.
Additional file 8: Immunohistochemistry for Interleukin 12.
Immunostaining for IL-12 (red) illustrated in representative skin samples
(counterstaining with haematoxylin). a) Overview of Ep and dermis in
inflamed skin. Ep, hairs (H) and sebaceous glands (G) stained immunopositive
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for IL-12 (red). b) Detail of Ep and Dpap. The strata granulosum, spinosum and
basale of the stratified squamous epithelium (Ep) showed a cytoplasmic red
staining for IL-12. Sebaceous glands (G) and hairs (H) usually stained positive
for IL-12. Musculi arrectores pilorum (Mm) were also positive for IL-12. In
addition, infiltrating leukocytes were frequently positive for IL-12 (arrows). c)
Epithelial ulcers. Ulcers (arrows) were unstained in otherwise IL-12-positive
stained squamous epithelium. Parts of the fibrocytes (asterisks) in Dpap also
stained positive for IL-12. d) Isotype control. No immunopositive staining is
visible in a similar localisation as in c).
Additional file 9: Immunohistochemistry for Interleukin 12 in
papillary dermis. Red immunoreactions for IL-12 are shown in
representative skin samples with haematoxylin counterstaining.
a) Detail of Dpap with adnexa. Epithelia of various kinds were usually
positive for IL-12, e.g. cortex and epithelial root sheath of hairs (H),
and glands and their excretory ducts (asterisks). Please note the
patchy staining pattern of the excretory ducts. Endothelia stained
positive (arrows) or negative (dashed arrows) for IL-12. Additionally,
Mm. arrectores pilorum (Mm) stained positive for IL-12. Fibrocytes
usually appeared negative for IL-12, but some perinuclear immunopositive
staining of fusiform cells in the connective tissue could be noted (circles). b)
Detail of Dpap illustrating appearance of apocrine glands. Apocrine glands
were positive for IL-12 (asterisks), but showed a patchy staining. Epithelial
components of hairs (H) were immunopositive, while fibrocytes in this detail
were negative for IL-12.c) Dpap – detail of subepithelial inflammation. Infiltrating
leukocytes can be found perivascularly and are dispersed diffusely in the
connective tissue. They frequently show a red perinuclear and cytoplasmic
immunostaining for IL-12 (arrows). Mm. arrectores pilorum (Mm) and
endothelia (dashed arrows) stained positive for IL-12, while fibrocytes were
usually negative for IL-12. Epithelium (Ep) and a gland (G) are indicated at
the edges of the image (top right and bottom left, respectively).
Additional file 10: Immunohistochemistry for Interleukin 12 in reticular
dermis. Immunostaining for IL-12 (red) in representative skin samples
(counterstaining with haematoxylin). a) Large artery and nerve in Dret. Walls
and endothelia (dashed arrows) of a large artery (A) and small blood vessels
stained positive for IL-12, as did the nerve (N). In addition, infiltrated leukocytes
(arrows) were positive for IL-12. Fibrocytes and extracellular matrix were usually
negative. b) Dret – detail with perivascular inflammation. Leukocytic perivascular
infiltration of high degree proximate to artery (A) and vein (V). In addition, vessel
walls and endothelia (arrows) infiltrated cells (asterisks) are positive for IL-12.
Fibrocytes and extracellular matrix are negative apart from a weak background
staining. c) Isotype control Dret with artery (A). All tissue components are
negative in detail of Dret.
Additional file 11: Immunohistochemistry for Interleukin 18. Illustration
of red IL-18 immunoreaction in representative skin samples (counterstained
with haematoxylin). a) Overview of Ep and dermis in mildly inflamed skin.
Ep (except for ulcers, arrows), hairs (H) and glands (G) stained positive for IL-18.
b) Isotype control – overview of Ep and dermis. No immunopositive staining
is visible in a similar localisation as in a) in the papillary layer. c) Detail of Ep
with ulcer (arrow) and Dpap with medium grade leukocyte infiltration. All
epithelial tissues [stratum granulosum, spinosum and basale of the stratified
squamous epithelium (Ep), cortex and epithelial root sheath of hairs
(arrowheads), sebaceous glands (G)] showed a cytoplasmic immunoreaction
for IL-18, while ulcers (arrow) were negative for IL-18. Infiltrating leukocytes
(arrowheads) were frequently positive for IL-18. The IL-18 staining of fibrocytes
and endothelia (dashed arrows) varied from positive to negative. d) Detail of
Ep and Dpap, isotype control. A corresponding section to c) did not show any
reaction for IL-18. Symbols: stratified squamous epithelium (Ep) with an ulcer
(arrow), hairs (cross-section, H), sebaceous glands (G), endothelia (dashed
arrows) and leukocyte infiltration (arrowheads). e) Detail of Dpap with vessels
and excretory ducts of apocrine glands (G). Blood vessel walls and endothelia
(dashed arrows) of a larger artery (A) and smaller vessels stained positive for
IL-18 (dashed arrows) usually appeared with immunopositive Lamina media
and endothelia (dashed arrows). Excretory ducts of apocrine glands (G) were
positive for IL-18. Fibrocytes and extracellular matrix were usually negative. f)
Detail of adnexa in Dpap. The epithelial root sheath of a hair (H) and Mm.
arrectores pilorum (Mm) always stained immunopositive for IL-18, while
apocrine glands (G) stained positive, but with some patchy appearance.
Fibrocytes and extracellular matrix were usually negative.
Additional file 12: Immunohistochemistry for Interleukin 18
(continued). Immunostaining for IL-18 (red) in representative skin samples
(counterstaining with haematoxylin). a) Dret – detail with perivascular
inflammation. Leukocytic perivascular infiltration is visible proximate to
artery (A) and vein (V). Vessel walls and endothelia (dashed arrows), as well
as infiltrated cells (arrows) are positive for IL-18. Fibrocytes and extracellular
matrix are negative, apart from a weak background staining. b) Cross-sectioned
nerve (N) in subcutis. Most parts of the nerve (N) stained immunopositive. In
addition, adjacent capillary endothelia were positive for IL-18 (dashed arrows).
c) Detail of infiltrated cells in Dpap. Infiltrating subepithelial immune cells were
usually positive for IL-18 (arrowheads), as well as capillary endothelia
(dashed arrows). Positive stratified squamous epithelium (Ep) and negative
basis of an ulcer (arrow) are visible at the top edge of the detail.
Additional file 13: Staining characteristics of IL-12 and IL-18 in IHC.
Detailed description of IL-12 and IL-18 stainings of skin biopsies.
Additional file 14: Influence of sex and type on systemic parameters.
Differences to individual baselines of a) WBC, b) neutrophils and c, d) TNFα
release (in medium only) of horses treated with DNA (groups B–D) calculated
at t12 and t24 are plotted in histograms for mares and geldings (a–c)
or Thoroughbreds (ThB) and Warmbloods (WBl) (d). Horizontal bars
represent mean and SD. Asterisks (*) with brackets (┌ ┐) represent significantly
different comparisons. The WBC, neutrophil and TNFα increases to individual
baselines after treatments with SAINT-18 formulated DNA were significantly
higher in mares than in geldings. Increases of TNFα releases were significantly
higher in ThB than in WBl.
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